Vivos Therapeutics Inc
Vivos Therapeutics, Inc. operates as a medical technology company that develops and commercializes treatment modalities for patients with dentofacial abnormalities, obstructive sleep apnea (OSA), and snoring in adults. It offers The Vivos Method, a non-invasive, non-surgical, non-pharmaceutical, multi-disciplinary treatment modality for the treatment of dentofacial abnormalities, OSA, and snoring… Read more
Vivos Therapeutics Inc (VVOS) - Net Assets
Latest net assets as of September 2025: $2.53 Million USD
Based on the latest financial reports, Vivos Therapeutics Inc (VVOS) has net assets worth $2.53 Million USD as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($25.64 Million) and total liabilities ($23.11 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $2.53 Million |
| % of Total Assets | 9.87% |
| Annual Growth Rate | 8.68% |
| 5-Year Change | -52.98% |
| 10-Year Change | N/A |
| Growth Volatility | 765.45 |
Vivos Therapeutics Inc - Net Assets Trend (2018–2024)
This chart illustrates how Vivos Therapeutics Inc's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Vivos Therapeutics Inc (2018–2024)
The table below shows the annual net assets of Vivos Therapeutics Inc from 2018 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $7.95 Million | +1835.28% |
| 2023-12-31 | $411.00K | -91.44% |
| 2022-12-31 | $4.80 Million | -81.20% |
| 2021-12-31 | $25.54 Million | +50.96% |
| 2020-12-31 | $16.92 Million | +674.82% |
| 2019-12-31 | $-2.94 Million | -160.97% |
| 2018-12-31 | $4.83 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Vivos Therapeutics Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 9166346800.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Other Components | $112.14 Million | 1409.87% |
| Total Equity | $7.95 Million | 100.00% |
Vivos Therapeutics Inc Competitors by Market Cap
The table below lists competitors of Vivos Therapeutics Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Compal Broadband Networks Inc
TW:6674
|
$9.26 Million |
|
PT Techno9 Indonesia Tbk
JK:NINE
|
$9.26 Million |
|
Panora Gayrimenkul Yatirim Ortakligi AS
IS:PAGYO
|
$9.27 Million |
|
Comfort Gloves Bhd
KLSE:2127
|
$9.27 Million |
|
Introl S.A.
WAR:INL
|
$9.26 Million |
|
Schwälbchen Molkerei Jakob Berz AG
F:SMB
|
$9.26 Million |
|
Altigen Communications Inc
OTCQB:ATGN
|
$9.26 Million |
|
Iondrive Ltd
AU:ION
|
$9.25 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Vivos Therapeutics Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 411,000 to 7,954,000, a change of 7,543,000 (1835.3%).
- Net loss of 11,136,000 reduced equity.
- New share issuances of 7,796,000 increased equity.
- Other factors increased equity by 10,883,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-11.14 Million | -140.01% |
| Share Issuances | $7.80 Million | +98.01% |
| Other Changes | $10.88 Million | +136.82% |
| Total Change | $- | 1835.28% |
Book Value vs Market Value Analysis
This analysis compares Vivos Therapeutics Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.83x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
- The price-to-book ratio has increased from 0.13x to 0.83x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2018-12-31 | $10.45 | $1.32 | x |
| 2019-12-31 | $-5.93 | $1.32 | x |
| 2020-12-31 | $23.23 | $1.32 | x |
| 2021-12-31 | $30.07 | $1.32 | x |
| 2022-12-31 | $5.22 | $1.32 | x |
| 2023-12-31 | $0.34 | $1.32 | x |
| 2024-12-31 | $1.58 | $1.32 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Vivos Therapeutics Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -140.01%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -74.09%
- • Asset Turnover: 0.98x
- • Equity Multiplier: 1.92x
- Recent ROE (-140.01%) is above the historical average (-609.89%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2018 | -176.97% | -225.25% | 0.46x | 1.70x | $-9.02 Million |
| 2019 | 0.00% | -94.39% | 1.51x | 0.00x | $-10.46 Million |
| 2020 | -71.27% | -92.28% | 0.52x | 1.50x | $-13.75 Million |
| 2021 | -79.46% | -120.18% | 0.50x | 1.32x | $-22.85 Million |
| 2022 | -496.67% | -148.81% | 1.17x | 2.86x | $-24.33 Million |
| 2023 | -3304.87% | -98.42% | 1.29x | 26.11x | $-13.62 Million |
| 2024 | -140.01% | -74.09% | 0.98x | 1.92x | $-11.93 Million |
Industry Comparison
This section compares Vivos Therapeutics Inc's net assets metrics with peer companies in the Medical Devices industry.
Industry Context
- Industry: Medical Devices
- Average net assets among peers: $694,749,556
- Average return on equity (ROE) among peers: -25.46%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Vivos Therapeutics Inc (VVOS) | $2.53 Million | -176.97% | 9.13x | $9.26 Million |
| Advanced Biomedical Technologies Inc (ABMT) | $-4.46 Million | 0.00% | 0.00x | $14.18K |
| Abbott Laboratories (ABT) | $4.82 Billion | 39.04% | 1.31x | $191.37 Billion |
| Acarix AB (publ) (ACIXF) | $1.93 Million | -127.02% | 0.21x | $26.42 Million |
| Adagio Medical Holdings, Inc Common Stock (ADGM) | $-72.62 Million | 0.00% | 0.00x | $4.05 Million |
| Adm Tronics Unltd (ADMT) | $-12.69K | 0.00% | 0.00x | $3.17 Million |
| Aethlon Medical Inc (AEMD) | $-3.07 Million | 0.00% | 0.00x | $2.79 Million |
| Acutus Medical Inc (AFIB) | $126.58 Million | -80.56% | 0.52x | $732.88K |
| Adapthealth Corp (AHCO) | $2.07 Billion | 7.56% | 1.54x | $914.25 Million |
| Allied Healthcare Products Inc. (AHPIQ) | $8.88 Million | -33.95% | 1.22x | $726.24 |
| 20/20 Biolabs, Inc. Common Stock (AIDX) | $3.39 Million | -59.65% | 0.38x | $9.18 Million |